Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Non-Current Assets (2016 - 2025)

Corcept Therapeutics' Non-Current Assets history spans 10 years, with the latest figure at $351.2 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 4.81% year-over-year to $351.2 million; the TTM value through Dec 2025 reached $1.4 billion, up 39.79%, while the annual FY2025 figure was $351.2 million, 4.81% down from the prior year.
  • Non-Current Assets for Q4 2025 was $351.2 million at Corcept Therapeutics, up from $282.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $408.0 million in Q1 2025 and bottomed at $77.3 million in Q2 2022.
  • The 5-year median for Non-Current Assets is $157.3 million (2021), against an average of $194.9 million.
  • The largest annual shift saw Non-Current Assets crashed 55.94% in 2022 before it skyrocketed 167.39% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $157.3 million in 2021, then plummeted by 46.48% to $84.2 million in 2022, then skyrocketed by 93.5% to $162.9 million in 2023, then surged by 126.52% to $369.0 million in 2024, then dropped by 4.81% to $351.2 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Non-Current Assets are $351.2 million (Q4 2025), $282.5 million (Q3 2025), and $358.6 million (Q2 2025).